T2 Biosystems announced the execution of territory exclusive distribution agreements for new geographies in the Netherlands, Belgium, and Vietnam, as well as the re-entry into Switzerland. Under the terms of the agreements, T2 Biosystems will sell the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, and the T2Resistance Panel into these countries through its distribution partners. The execution of these territory exclusive distribution agreements further expands T2 Biosystems’ commercial business internationally. Finally, T2 Biosystems’ current distribution partner Biomedica, which secured the company’s second largest T2Dx Instrument contract in company history during 2023 in Poland, is re-entering the Switzerland market with T2 Biosystems’ sepsis products.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TTOO:
- T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results
- T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia
- T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity
- TTOO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel
